Suppr超能文献

经导管主动脉瓣置换术治疗心房颤动患者全因死亡率的预测因素。

Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial Fibrillation.

机构信息

Department of Cardiology, Toyohashi Heart Center, Aichi, Japan.

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

出版信息

Am J Cardiol. 2023 Nov 15;207:150-158. doi: 10.1016/j.amjcard.2023.08.067. Epub 2023 Sep 21.

Abstract

Prevalent and incident atrial fibrillation are common in patients who undergo transcatheter aortic valve implantation and are associated with impaired postprocedural outcomes, including mortality. We determined predictors of long-term mortality in patients with atrial fibrillation after successful transcatheter aortic valve implantation. The EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation-Atrial Fibrillation (ENVISAGE-TAVI AF) trial (NCT02943785) was a multicenter, prospective, randomized controlled trial in patients with prevalent or incident atrial fibrillation after successful transcatheter aortic valve implantation who received edoxaban or vitamin K antagonists. A Cox proportional hazard model was performed to identify predictors of all-cause mortality using a stepwise approach for multiple regression analysis. In addition, we assessed the performance of different risk scores and prediction models using ENVISAGE-TAVI AF data. Of 1,426 patients in ENVISAGE-TAVI AF, 178 (12.5%) died during the follow-up period (median 548 days). Our stepwise approach identified greater risk of mortality with older age, impaired renal function, nonparoxysmal atrial fibrillation, excessive alcohol use, New York Heart Association heart failure class III/IV, peripheral artery disease, and history of major bleeding or predisposition to bleeding. The present model (concordance statistic [c-statistic] 0.67) was a better discriminator than were other frequently used risk scores, such as the Society of Thoracic Surgeons score (c-statistic 0.56); Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke, Vascular disease, Age 65 to 74 years, and Sex category (CHADS-VASc) score (c-statistic 0.54); or Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly, and Drugs/alcohol concomitantly (HAS-BLED) score (c-statistic 0.58). In ENVISAGE-TAVI AF, several modifiable and nonmodifiable clinical characteristics were significantly associated with greater long-term all-cause mortality. Improved risk stratification to estimate the probability of mortality after successful transcatheter aortic valve implantation in patients with atrial fibrillation may improve long-term patient prognosis.

摘要

在接受经导管主动脉瓣植入术的患者中,普遍存在和新发的心房颤动与术后预后受损相关,包括死亡率。我们确定了经导管主动脉瓣植入术后心房颤动患者长期死亡率的预测因素。EdoxabaN 与标准治疗的比较及其对经导管主动脉瓣植入术后有房颤患者的临床结局的影响(ENVISAGE-TAVI AF)试验(NCT02943785)是一项多中心、前瞻性、随机对照试验,纳入了成功接受经导管主动脉瓣植入术后患有持续性或新发心房颤动的患者,这些患者接受了依度沙班或维生素 K 拮抗剂。采用逐步多元回归分析方法,通过 Cox 比例风险模型确定全因死亡率的预测因素。此外,我们使用 ENVISAGE-TAVI AF 数据评估了不同风险评分和预测模型的性能。在 ENVISAGE-TAVI AF 中,1426 例患者中有 178 例(12.5%)在随访期间死亡(中位数 548 天)。我们的逐步方法确定了以下因素与更高的死亡率相关:年龄较大、肾功能受损、非阵发性心房颤动、过量饮酒、纽约心脏协会心力衰竭分级 III/IV 级、外周动脉疾病以及有大出血史或易出血倾向。该模型(一致性统计量 [c 统计量] 0.67)比其他常用风险评分,如胸外科医生评分(c 统计量 0.56);充血性心力衰竭、高血压、年龄≥75 岁、糖尿病、中风、血管疾病、65 至 74 岁年龄组和性别类别(CHADS-VASc)评分(c 统计量 0.54);或高血压、肝肾功能异常、中风、出血史或倾向、不稳定的国际标准化比值、老年和同时使用药物/酒精(HAS-BLED)评分(c 统计量 0.58)更好地鉴别。在 ENVISAGE-TAVI AF 中,几个可改变和不可改变的临床特征与更高的长期全因死亡率显著相关。改善风险分层以估计接受经导管主动脉瓣植入术的心房颤动患者的死亡率概率,可能会改善长期患者预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验